Impact	0	6	O
of	7	9	O
tumor	10	15	B-Cell
cell	16	20	I-Cell
VEGF	21	25	B-Gene_or_gene_product
expression	26	36	O
on	37	39	O
the	40	43	O
in	44	46	O
vivo	47	51	O
efficacy	52	60	O
of	61	63	O
vandetanib	64	74	B-Drug_or_compound
(	75	76	O
ZACTIMA	76	83	B-Drug_or_compound
;	83	84	O
ZD6474	85	91	B-Drug_or_compound
)	91	92	O
.	92	93	O

VEGF	95	99	B-Gene_or_gene_product
is	100	102	O
the	103	106	O
key	107	110	O
player	111	117	O
in	118	120	O
tumor	121	126	B-Pathological_formation
angiogenesis	127	139	O
.	139	140	O

In	141	143	O
the	144	147	O
current	148	155	O
study	156	161	O
,	161	162	O
the	163	166	O
impact	167	173	O
of	174	176	O
VEGF	177	181	B-Gene_or_gene_product
expression	182	192	O
on	193	195	O
the	196	199	O
response	200	208	O
of	209	211	O
tumors	212	218	B-Pathological_formation
to	219	221	O
the	222	225	O
VEGFR2	226	232	B-Gene_or_gene_product
associated	233	243	O
tyrosine	244	252	O
kinase	253	259	O
inhibitor	260	269	O
vandetanib	270	280	B-Drug_or_compound
was	281	284	O
evaluated	285	294	O
.	294	295	O

MATERIALS	296	305	O
AND	306	309	O
METHODS	310	317	O
:	317	318	O
Human	319	324	B-Organism
colon	325	330	B-Pathological_formation
carcinoma	331	340	I-Pathological_formation
(	341	342	O
HT29	342	346	B-Cell
)	346	347	O
and	348	351	O
murine	352	358	B-Organism
squamous	359	367	B-Pathological_formation
carcinoma	368	377	I-Pathological_formation
(	378	379	O
SCCVII	379	385	B-Cell
)	385	386	O
clonal	387	393	O
cell	394	398	B-Cell
lines	399	404	I-Cell
expressing	405	415	O
varying	416	423	O
levels	424	430	O
of	431	433	O
VEGF	434	438	B-Gene_or_gene_product
were	439	443	O
established	444	455	O
and	456	459	O
their	460	465	O
response	466	474	O
to	475	477	O
vandetanib	478	488	B-Drug_or_compound
was	489	492	O
assessed	493	501	O
in	502	504	O
tissue	505	511	B-Tissue
culture	512	519	O
and	520	523	O
as	524	526	O
solid	527	532	B-Pathological_formation
tumors	533	539	I-Pathological_formation
.	539	540	O

RESULTS	541	548	O
:	548	549	O
Vandetanib	550	560	B-Drug_or_compound
treatment	561	570	O
had	571	574	O
no	575	577	O
effect	578	584	O
on	585	587	O
tumor	588	593	B-Cell
cell	594	598	I-Cell
clonogenic	599	609	O
cell	610	614	B-Cell
survival	615	623	O
in	624	626	O
vitro	627	632	O
but	633	636	O
doses	637	642	O
>	643	644	O
or	644	646	O
=	646	647	O
10	647	649	O
nM	650	652	O
significantly	653	666	O
reduced	667	674	O
endothelial	675	686	B-Cell
cell	687	691	I-Cell
migration	692	701	O
.	701	702	O

In	703	705	O
vivo	706	710	O
,	710	711	O
tumors	712	718	B-Pathological_formation
derived	719	726	O
from	727	731	O
cell	732	736	B-Cell
clones	737	743	I-Cell
expressing	744	754	O
high	755	759	O
levels	760	766	O
of	767	769	O
VEGF	770	774	B-Gene_or_gene_product
displayed	775	784	O
significantly	785	798	O
enhanced	799	807	O
angiogenesis	808	820	O
and	821	824	O
more	825	829	O
aggressive	830	840	O
growth	841	847	O
.	847	848	O

An	849	851	O
intradermal	852	863	B-Multi-tissue_structure
angiogenesis	864	876	O
assay	877	882	O
was	883	886	O
used	887	891	O
to	892	894	O
demonstrate	895	906	O
that	907	911	O
a	912	913	O
4	914	915	O
-	915	916	O
day	916	919	O
treatment	920	929	O
with	930	934	O
vandetanib	935	945	B-Drug_or_compound
(	946	947	O
50	947	949	O
mg	950	952	O
/	952	953	O
kg	953	955	O
/	955	956	O
day	956	959	O
)	959	960	O
was	961	964	O
able	965	969	O
to	970	972	O
significantly	973	986	O
inhibit	987	994	O
blood	995	1000	B-Multi-tissue_structure
vessel	1001	1007	I-Multi-tissue_structure
growth	1008	1014	O
induced	1015	1022	O
by	1023	1025	O
both	1026	1030	O
parental	1031	1039	O
and	1040	1043	O
high	1044	1048	O
VEGF	1049	1053	B-Gene_or_gene_product
-	1053	1054	O
expressing	1054	1064	O
tumor	1065	1070	B-Cell
cell	1071	1075	I-Cell
clones	1076	1082	O
.	1082	1083	O

In	1084	1086	O
the	1087	1090	O
HT29	1091	1095	B-Pathological_formation
tumor	1096	1101	I-Pathological_formation
model	1102	1107	O
,	1107	1108	O
treatment	1109	1118	O
response	1119	1127	O
to	1128	1130	O
vandetanib	1131	1141	B-Drug_or_compound
(	1142	1143	O
50	1143	1145	O
mg	1146	1148	O
/	1148	1149	O
kg	1149	1151	O
/	1151	1152	O
day	1152	1155	O
,	1155	1156	O
Monday	1157	1163	O
-	1163	1164	O
Friday	1164	1170	O
for	1171	1174	O
2	1175	1176	O
weeks	1177	1182	O
)	1182	1183	O
was	1184	1187	O
greatest	1188	1196	O
in	1197	1199	O
xenografts	1200	1210	O
derived	1211	1218	O
from	1219	1223	O
the	1224	1227	O
highest	1228	1235	O
VEGF	1236	1240	B-Gene_or_gene_product
-	1240	1241	O
expressing	1241	1251	O
cell	1252	1256	B-Cell
clones	1257	1263	I-Cell
.	1263	1264	O

A	1265	1266	O
similar	1267	1274	O
trend	1275	1280	O
was	1281	1284	O
noted	1285	1290	O
in	1291	1293	O
the	1294	1297	O
SCCVII	1298	1304	B-Pathological_formation
tumor	1305	1310	I-Pathological_formation
model	1311	1316	O
.	1316	1317	O

The	1318	1321	O
present	1322	1329	O
findings	1330	1338	O
indicate	1339	1347	O
that	1348	1352	O
vandetanib	1353	1363	B-Drug_or_compound
therapy	1364	1371	O
effectively	1372	1383	O
counteracted	1384	1396	O
the	1397	1400	O
aggressive	1401	1411	O
feature	1412	1419	O
of	1420	1422	O
tumor	1423	1428	B-Pathological_formation
growth	1429	1435	O
resulting	1436	1445	O
from	1446	1450	O
VEGF	1451	1455	B-Gene_or_gene_product
over	1456	1460	O
-	1460	1461	O
expressing	1461	1471	O
tumor	1472	1477	B-Cell
cells	1478	1483	I-Cell
and	1484	1487	O
suggest	1488	1495	O
that	1496	1500	O
such	1501	1505	O
tumors	1506	1512	B-Pathological_formation
may	1513	1516	O
be	1517	1519	O
particularly	1520	1532	O
well	1533	1537	O
suited	1538	1544	O
for	1545	1548	O
anti	1549	1553	O
-	1553	1554	O
VEGF	1554	1558	B-Gene_or_gene_product
interventions	1559	1572	O
.	1572	1573	O

